Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

1.

Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.

van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS.

Rheumatology (Oxford). 2012 Oct;51(10):1894-905. Epub 2012 Jul 6.

PMID:
22772319
[PubMed - indexed for MEDLINE]
Free Article
2.

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9.

PMID:
19740906
[PubMed - indexed for MEDLINE]
3.

The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.

Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J.

Rheumatology (Oxford). 2011 Aug;50(8):1466-72. doi: 10.1093/rheumatology/ker087. Epub 2011 Mar 26.

PMID:
21441550
[PubMed - indexed for MEDLINE]
Free Article
4.

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.

van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R; Assessment of SpondyloArthritis international Society (ASAS).

Ann Rheum Dis. 2009 Dec;68(12):1811-8. doi: 10.1136/ard.2008.100826. Epub 2008 Dec 5.

PMID:
19060001
[PubMed - indexed for MEDLINE]
5.

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, Weiß A, Djacenko S, Burmester GR, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J.

Ann Rheum Dis. 2012 Jul;71(7):1212-5. doi: 10.1136/annrheumdis-2011-201010. Epub 2012 Mar 22.

PMID:
22440819
[PubMed - indexed for MEDLINE]
6.

Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.

Chou CT, Tsai CY, Liang TH, Chang TM, Lai CH, Wei CC, Chen KH, Lin SC, Yu CL, Liou LB, Luo SF, Lee CS, Hsue YT, Huang CM, Chen JH, Lai NS, Cheng HH, Cheng TT, Lai HM, Tsai WC, Yen JH, Lu LY, Chang CP.

Mod Rheumatol. 2010 Dec;20(6):580-7. doi: 10.1007/s10165-010-0334-2. Epub 2010 Aug 4.

PMID:
20683633
[PubMed - indexed for MEDLINE]
7.

Etanercept in the longterm treatment of patients with ankylosing spondylitis.

Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J.

J Rheumatol. 2009 Jun;36(6):1256-64. doi: 10.3899/jrheum.081033. Epub 2009 May 1. Erratum in: J Rheumatol. 2010 Oct;37(10):2198.

PMID:
19411393
[PubMed - indexed for MEDLINE]
8.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group.

Arthritis Rheum. 2003 Nov;48(11):3230-6.

PMID:
14613288
[PubMed - indexed for MEDLINE]
Free Article
9.

Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.

Davis JC Jr, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.

J Rheumatol. 2005 Sep;32(9):1751-4.

PMID:
16142873
[PubMed - indexed for MEDLINE]
10.

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J.

Arthritis Res Ther. 2013;15(3):R67.

PMID:
23786760
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.

Ann Rheum Dis. 2004 Dec;63(12):1594-600. Epub 2004 Sep 2.

PMID:
15345498
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

PMID:
12794835
[PubMed - indexed for MEDLINE]
Free Article
13.
14.

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.

Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.

Ann Rheum Dis. 2008 Mar;67(3):346-52. Epub 2007 Oct 29.

PMID:
17967833
[PubMed - indexed for MEDLINE]
Free Article
15.

Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis.

Hendrix S, Koenig A, Li W, Singh A.

J Int Med Res. 2013 Oct;41(5):1606-11. doi: 10.1177/0300060513496171. Epub 2013 Aug 23.

PMID:
23975857
[PubMed - indexed for MEDLINE]
16.

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.

Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B.

Arthritis Rheum. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223.

PMID:
21630245
[PubMed - indexed for MEDLINE]
Free Article
17.

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.

Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.

Ann Rheum Dis. 2005 Nov;64(11):1557-62. Epub 2005 Apr 20.

PMID:
15843448
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.

van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS.

Ann Rheum Dis. 2013 Jul;72(7):1221-4. doi: 10.1136/annrheumdis-2012-202431. Epub 2012 Dec 22.

PMID:
23264358
[PubMed - indexed for MEDLINE]
19.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2005 Dec 15;53(6):856-63.

PMID:
16342093
[PubMed - indexed for MEDLINE]
Free Article
20.

MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.

Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D.

Ann Rheum Dis. 2012 Dec;71(12):2002-5. doi: 10.1136/annrheumdis-2012-201999. Epub 2012 Aug 21.

PMID:
22915615
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk